Janet Leeds Net Worth

Janet Leeds biography

Janet Leeds serves as Independent Director of the Company. Ms. Leeds has served on the Board since January 2019. Ms. Leeds has held a number of leadership and consulting roles in academic healthcare settings over more than thirty years. Currently, Ms. Leeds serves as an Administrative Director at the Seattle Cancer Care Alliance (SCCA), a cancer center comprising Fred Hutchinson Cancer Research Center, Seattle Children’s Hospital and UW Medicine. From 2005 to 2009, Ms. Leeds served as the Administrator for the Fred Hutchinson/University of Washington Cancer Consortium. From 2000 to 2005, Ms. Leeds served as the Director of Planning at the Fred Hutchinson Cancer Research Center. From 1996 to 2000, Ms. Leeds served in various positions that were instrumental to the formation and development of the SCCA. Prior to that, from 1987 to 1995, Ms. Leeds held management consultant positions of increasing responsibility at ECG Management Consultants, where she primarily consulted with academic medical centers. Ms. Leeds received a B.A. from Stanford University and an M.B.A. from the University of Washington.

What is the salary of Janet Leeds?

As the Independent Director of Penumbra Inc, the total compensation of Janet Leeds at Penumbra Inc is $319,931. There are 9 executives at Penumbra Inc getting paid more, with Johanna Roberts having the highest compensation of $2,556,370.

How old is Janet Leeds?

Janet Leeds is 58, she's been the Independent Director of Penumbra Inc since 2019. There are 4 older and 11 younger executives at Penumbra Inc. The oldest executive at Penumbra Inc is Don Kassing, 78, who is the Presiding Independent Director.

What's Janet Leeds's mailing address?

Janet's mailing address filed with the SEC is ONE PENUMBRA PLACE, , ALAMEDA, CA, 94502.

Insiders trading at Penumbra Inc

Over the last 9 years, insiders at Penumbra Inc have traded over $197,637,326 worth of Penumbra Inc stock and bought 700 units worth $109,480 . The most active insiders traders include Adam Elsesser, Arani Bose, and James Robert Pray. On average, Penumbra Inc executives and independent directors trade stock every 9 days with the average trade being worth of $2,030,383. The most recent stock trade was executed by Harpreet Grewal on 4 September 2024, trading 782 units of PEN stock currently worth $159,614.

What does Penumbra Inc do?

penumbra is a specialty interventional therapies company that develops and markets innovative medical devices to treat challenging medical conditions with significant unmet clinical needs. we design our therapies to provide our specialist physician customers with improved clinical outcomes through faster and safer procedures at significant overall cost savings to the healthcare system. today we have over 1,000 employees with sales operations in north america, europe, australia and asia.

Penumbra Inc executives and stock owners

Penumbra Inc executives and other stock owners filed with the SEC include:

• Johanna Roberts,
  Executive Vice President, General Counsel, Secretary
• Maggie Yuen,
  Chief Financial Officer
• Adam Elsesser,
  Chairman of the Board, Chief Executive Officer
• Lynn Rothman,
  Executive Vice President, Chief Business Officer
• Maggie S. Yuen,
  Chief Financial Officer
• James Pray,
  President, International
• Arani Bose,
  Chief Innovator, Director
• Johanna Roberts,
  Exec. VP, Gen. Counsel & Sec.
• Lambert Shiu,
  Chief Accounting Officer
• Janet Leeds,
  Independent Director
• Surbhi Sarna,
  Independent Director
• Adam Elsesser,
  Co-Founder, Chairman, Pres & CEO
• Harpreet Grewal,
  Independent Director
• Bridget O'Rourke,
  Independent Director
• Thomas Wilder,
  Independent Director
• Don Kassing,
  Presiding Independent Director
• Lambert Shiu,
  Chief Accounting Officer
• Gita Barry,
  Exec. VP & GM of Immersive Healthcare
• Ben Tompkins,
  Exec. VP of Devel.
• Shruthi Narayan,
  Director of Marketing - Vascular
• Dr. Arani Bose M.D.,
  Co-Founder & Director
• Jee Hamlyn-Harris,
  Investor Relations Officer
• Corey L. Teigen M.D.,
  Chief Scientific Officer
• Ben Sorci,
  Exec. VP of Operations
• Kevin James Sullivan,
  Director
• Robert D. Evans,
  EVP, Gen. Counsel & Secretary
• Daniel Donen Davis,
  President, North America
• Sridhar Kosaraju,
  President
• Walter Charles Wang,
  Director